Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 101–200 of 1,017
Shady, W., Petre, E. N., Gonen, M., Erinjeri, J. P., Brown, K. T., Covey, A. M., Alago, W., Durack, J. C., Maybody, M., Brody, L. A., et al. (2016) · Radiology · doi:10.1148/radiol.2015142489 · Cited by 373
Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality
Aran, V., Victorino, A. P., Thuler, L. C., & Ferreira, C. G. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.02.008 · Cited by 365
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
“Patients and Study Designs of the CRYSTAL and OPUS Studies All patients had previously untreated mCRC; study designs and key eligibility and exclusion criteria have previously been described in detail.(1,3) All patients provided written informed consent, and the studies were carried out in accordance with the Declarat…”
MethodSelf-citationPersonalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
A pathway-based classification of human breast cancer
Gatza, M. L., Lucas, J. E., Barry, W. T., Kim, J. W., Wang, Q., D. Crawford, M., B. Datto, M., Kelley, M., Mathey-Prevot, B., Potti, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912708107 · Cited by 347
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Rectal and colon cancer: Not just a different anatomic site
Tamas, K., Walenkamp, A. M. E., de Vries, E. G. E., van Vugt, M. A. T. M., Beets-Tan, R. G., van Etten, B., de Groot, D. J. A., & Hospers, G. A. P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.007 · Cited by 331
Tabernero, J., Lenz, H.-J., Siena, S., Sobrero, A., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00138-2 · Cited by 328
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Sartore-Bianchi, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 329
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“Two representative examples of such drugs are cetuximab and panitumumab, two monoclonal antibodies (moAbs) against the epidermal growth factor receptor (EGFR), which have been proven to be effective for patients with RAS wild type (RASWT) mCRC in randomized clinical trials [3-9].”
BackgroundGenetics, diagnosis and management of colorectal cancer (Review)
DE ROSA, M., PACE, U., REGA, D., COSTABILE, V., DURATURO, F., IZZO, P., & DELRIO, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4108 · Cited by 317
Combinational strategy for high-performance cancer chemotherapy
Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 301
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
“Cetuximab and panitumumab have shown efficacy both as monotherapy (Amado et al, 2008; Karapetis et al, 2008) and in combination with chemotherapy (Tol et al, 2009; Van Cutsem et al, 2009) in patients with KRAS wild-type metastatic CRC.”
Stewart, C. L., Warner, S., Ito, K., Raoof, M., Wu, G. X., Kessler, J., Kim, J. Y., & Fong, Y. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.08.004 · Cited by 287
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
Cinausero, M., Aprile, G., Ermacora, P., Basile, D., Vitale, M. G., Fanotto, V., Parisi, G., Calvetti, L., & Sonis, S. T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00354 · Cited by 290
“Notably, in the CRYSTAL trial, colorectal cancer patients randomized to receive FOLFIRI plus cetuximab showed higher frequency of grades 3 and 4 GIM than patients receiving FOLFIRI alone (Van Cutsem et al., 2009, 2011).”
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
“A retrospective subgroup analysis demonstrated that patients who had wild-type KRAS and were treated with the cetuximab–FOLFIRI regime”
MethodColorectal liver metastases: Current management and future perspectives
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 275
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
Goéré, D., Malka, D., Tzanis, D., Gava, V., Boige, V., Eveno, C., Maggiori, L., Dumont, F., Ducreux, M., & Elias, D. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31827e9289 · Cited by 272
“Lymph nodes 9 (8) Bone 4 (4) Soft tissues 3 (3) Adrenal 1 (1)”
BackgroundKhambata-Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L.-A., Horak, C. E., Dakhil, S., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 266
“Presence of K-Ras mutations seems to confer lack of benefit from tyrosine kinase inhibitor (TKI) –based therapy in NSCLC(11-13) and also from cetuximab in mCRC.(6,7,14) Compared with wild-type EGFR, activating EGFR mutations—present on tumors of approximately 10% of white and up to 50% of Asian patients with advanced…”
BackgroundSirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., Leedham, S. J., Chatzipli, A., Hardy, C., Whalley, C. M., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319866 · Cited by 264
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
“In these individuals, response to EGFR blockade can result in remarkable tumor regressions, but these are short lived (16) and progression occurs within months (17).”
Role of surgery in colorectal cancer liver metastases
Akgül, Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6113 · Cited by 259
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M. H., Song, J., Li, L., Dagenborg, V. J., Fretland, Å. A., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002319 · Cited by 260
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
A comprehensive framework for early-onset colorectal cancer research
Eng, C., Jácome, A. A., Agarwal, R., Hayat, M. H., Byndloss, M. X., Holowatyj, A. N., Bailey, C., & Lieu, C. H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00588-x · Cited by 241
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar, E., Johnson, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 253
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30798-3 · Cited by 255
Morelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Janku, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 249
“Although it might be assumed that patients with KRAS -mutated carcinomas (mostly adenocarcinomas) would be resistant to anti-EGFR targeted therapy similar to patients with metastatic colorectal cancer and mutated KRAS”
BackgroundSpindler, K.-L. G., Pallisgaard, N., Vogelius, I., & Jakobsen, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0564 · Cited by 251
The molecular genetics of colorectal cancer
Ewing, I., Hurley, J. J., Josephides, E., & Millar, A. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100329 · Cited by 249
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012153 · Cited by 244
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultPeeters, M., Oliner, K. S., Parker, A., Siena, S., Van Cutsem, E., Huang, J., Humblet, Y., Van Laethem, J.-L., André, T., Wiezorek, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1913 · Cited by 243
“Prior analyses of KRASmutational status in anti-EGFRmonoclonal antibody therapy have primarily assessed mutations only in codons 12and13 (1, 3, 6, 14, 27); however, 1 study reported that no patients with mutations in codon 61 (n 1⁄4 8) responded to treatment with cetuximab plus irinotecan (28).”
Sun, L., Shen, F., Tian, L., Tao, H., Xiong, Z., Xu, J., & Liu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202007910 · Cited by 243
Gruenberger, B., Schueller, J., Heubrandtner, U., Wrba, F., Tamandl, D., Kaczirek, K., Roka, R., Freimann-Pircher, S., & Gruenberger, T. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70247-3 · Cited by 247
Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Del Monte, F., Cortesi, E., Amoroso, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3183 · Cited by 237
“safety of first-line cetuximab plus leucovorin, FU, and irinotecan (FOLFIRI) versus FOLFIRI alone; inclusion criteria focused on tumor EGFR expression rather than KRAS/RAS mutational status.(3) Retrospective analysis of patients with KRAS exon 2 wt tumors showed that adding cetuximab to FOLFIRI significantly improved”
MethodMetastatic Colorectal Cancer: From Improved Survival to Potential Cure
Gallagher, D. J., & Kemeny, N. (2010) · Oncology · doi:10.1159/000315730 · Cited by 235
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
“The chimeric IgG1 therapeutic antibody cetuximab targets EGFR in colorectal cancer (CRC) and has like trastuzumab ADCC and abrogation of tumor cell signaling as the modes of action (Table 1) (Van Cutsem et al., 2009).”
BackgroundPeeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 227
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
Shaw, A. T., Winslow, M. M., Magendantz, M., Ouyang, C., Dowdle, J., Subramanian, A., Lewis, T. A., Maglathin, R. L., Tolliday, N., & Jacks, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105941108 · Cited by 230
Designing nanomedicine for immuno-oncology
Jiang, W., von Roemeling, C. A., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 229
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25555 · Cited by 227
Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq588 · Cited by 229
Self-citationWei, Z., Cao, S., Liu, S., Yao, Z., Sun, T., Li, Y., Li, J., Zhang, D., & Zhou, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10064 · Cited by 222
“Moreover, as obvious benefits of anti-epidermal growth factor receptor therapy were shown in patients with KRAS mutations [44, 45] and sensitivity to irinotecan was found in the MLH1 deficiency cell model [46, 47], our finding poses the question as to whether patients that suffered from dysbiosis should receive more a…”
BackgroundFabbri, F., Carloni, S., Zoli, W., Ulivi, P., Gallerani, G., Fici, P., Chiadini, E., Passardi, A., Frassineti, G. L., Ragazzini, A., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.015 · Cited by 223
Nanotheranostics for personalized medicine
Kim, T. H., Lee, S., & Chen, X. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.15 · Cited by 222
Piessevaux, H., Buyse, M., Schlichting, M., Van Cutsem, E., Bokemeyer, C., Heeger, S., & Tejpar, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8532 · Cited by 222
Self-citationComparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Salem, M. E., Weinberg, B. A., Xiu, J., El-Deiry, W. S., Hwang, J. J., Gatalica, Z., Philip, P. A., Shields, A. F., Lenz, H.-J., & Marshall, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21169 · Cited by 216
“These differences offer insight into the potential use of EGFR inhibitors due to the fact that only patients with RAS and BRAF wild-type tumors derive benefit [10, 11] (although results from the study by Venook and colleagues suggested that cetuximab might actually be detrimental to patients with right-sided tumors, r…”
ResultRecent Therapeutic Advances in the Treatment of Colorectal Cancer
Ciombor, K. K., Wu, C., & Goldberg, R. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051513-102539 · Cited by 215
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 219
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases
Brudvik, K. W., Kopetz, S. E., Li, L., Conrad, C., Aloia, T. A., & Vauthey, J.-N. (2015) · British Journal of Surgery · doi:10.1002/bjs.9870 · Cited by 214
Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?
Dueland, S., Guren, T. K., Hagness, M., Glimelius, B., Line, P.-D., Pfeiffer, P., Foss, A., & Tveit, K. M. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000786 · Cited by 212
Colorectal Cancer Biomarkers: Where Are We Now?
Gonzalez-Pons, M., & Cruz-Correa, M. (2015) · BioMed Research International · doi:10.1155/2015/149014 · Cited by 209
Predictive and prognostic molecular markers for cancer medicine
Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., & Print, C. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009360519 · Cited by 210
Díaz-Rubio, E., Gómez-España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., Martínez de Prado, P., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210
“The PFS results obtained in both arms of our study are consistent with data reported from other studies using combinations of chemotherapy with bevacizumab [9, 10, 26] or with cetuximab or panitumumab in the wild-type KRAS population [27–29].”
ResultTol, J., Dijkstra, J. R., Klomp, M., Teerenstra, S., Dommerholt, M., Vink-Börger, M. E., van Cleef, P. H., van Krieken, J. H., Punt, C. J. A., & Nagtegaal, I. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.036 · Cited by 210
Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq714 · Cited by 206
Nanolongan with Multiple On-Demand Conversions for Ferroptosis–Apoptosis Combined Anticancer Therapy
Bao, W., Liu, X., Lv, Y., Lu, G.-H., Li, F., Zhang, F., Liu, B., Li, D., Wei, W., & Li, Y. (2019) · ACS Nano · doi:10.1021/acsnano.8b05602 · Cited by 206
O'Byrne, K. J., Gatzemeier, U., Bondarenko, I., Barrios, C., Eschbach, C., Martens, U. M., Hotko, Y., Kortsik, C., Paz-Ares, L., Pereira, J. R., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70189-9 · Cited by 205
Self-citationBodnar, R. J. (2013) · Advances in Wound Care · doi:10.1089/wound.2011.0326 · Cited by 202
“In addition, clinical studies have demonstrated that the use of EGFRi improved survival rates, making it a valid target for anticancer therapy.(19,20) There are five Federal Drug Administration–approved EGFRi drugs and their increased use has cause the development of a sever skin rash and the formation of pustules on…”
BackgroundAXL Mediates Resistance to Cetuximab Therapy
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Luthar, N., Toulany, M., Gill, P. S., Salgia, R., Kimple, R. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0294 · Cited by 198
“In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non–small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL was overexpressed, activated, and tightly associated with EGFR…”
InfluentialKRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., Hantel, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1570 · Cited by 194
Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer
Uhlitz, F., Bischoff, P., Peidli, S., Sieber, A., Trinks, A., Lüthen, M., Obermayer, B., Blanc, E., Ruchiy, Y., Sell, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114123 · Cited by 196
Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191
“Several studies have unequivocally demonstrated that mutations of the KRAS gene, which occur in 35 to 40% of CRCs, are associated with extremely low response rates to anti-EGFR antibodies (5-13).”
Heinemann, V., Stintzing, S., Modest, D. P., Giessen-Jung, C., Michl, M., & Mansmann, U. R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.116 · Cited by 185
“In first-line treatment, the addition of targeted therapies, such as the epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies (mAbs) cetuximab and panitumumab and the vascular endothelial growth factor (VEGF)-targeting mAb bevacizumab to standard combination chemotherapy regimens, has led to a marke…”
BackgroundMethodMasi, G., Vasile, E., Loupakis, F., Cupini, S., Fornaro, L., Baldi, G., Salvatore, L., Cremolini, C., Stasi, I., Brunetti, I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq456 · Cited by 188
Lam, V. W. T., Spiro, C., Laurence, J. M., Johnston, E., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2061-0 · Cited by 186
Garufi, C., Torsello, A., Tumolo, S., Ettorre, G. M., Zeuli, M., Campanella, C., Vennarecci, G., Mottolese, M., Sperduti, I., & Cognetti, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605940 · Cited by 185
“…FA, CPT-11) or FOLFOX (5-FU, FA, L-OHP) has been shown to increase response rates, and prolong progression-free survival (PFS) and overall survival (OS) times in the first-line treatment of patients with metastatic CRC and KRAS wild-type tumours (Bokemeyer et al, 2009; Van Cutsem et al, 2009).”
BackgroundInfluentialTejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 185
Self-citationAre there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Asghar, U., & Meyer, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.031 · Cited by 182
“The anti-EGFR antibodies cetuximab and panitumumab, have also been effectively combined with chemotherapy in colorectal cancer [34,35] where response has been linked to KRAS mutational status.”
BackgroundLee, A. M., Shi, Q., Pavey, E., Alberts, S. R., Sargent, D. J., Sinicrope, F. A., Berenberg, J. L., Goldberg, R. M., & Diasio, R. B. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju298 · Cited by 189
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
“These initial studies evaluated the most commonly occurring mutations in codons 12 and 11 13 of KRAS; predictive value of KRAS mutations beyond exon 2 and mutations in other RAS 12 enzymes (such as NRAS) were not assessed (6-9).”
BackgroundTrinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0680 · Cited by 180
Quenet, F., Goéré, D., Mehta, S. S., Roca, L., Dumont, F., Hessissen, M., Saint-Aubert, B., & Elias, D. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182263933 · Cited by 180
A Review on Notch Signaling and Colorectal Cancer
Tyagi, A., Sharma, A. K., & Damodaran, C. (2020) · Cells · doi:10.3390/cells9061549 · Cited by 179
“Despite an apparent decrease in CRC-related morbidity in the past decade, metastatic CRC remains difficult to treat and thus has high mortality rates [2,3].”
BackgroundColorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
“Later, the CRYSTAL III trial showed that the combination of cetuximab with FOLFIRI decreased the risk of progression of the disease by 15% in patients with mCRC compared to FOLFIRI therapy alone [hazard ratio (HR) = 0.85; P = 0.048][98].”
InfluentialBiomarker enrichment strategies: matching trial design to biomarker credentials
Freidlin, B., & Korn, E. L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.218 · Cited by 177
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176
Smith, G., Bounds, R., Wolf, H., Steele, R. J. C., Carey, F. A., & Wolf, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605534 · Cited by 174
“K-Ras mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008;…”
BackgroundInfluentialHow many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 177
Modjtahedi, H., & Essapen, S. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283330590 · Cited by 175
Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Hoefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 177
Lordick, F., Luber, B., Lorenzen, S., Hegewisch-Becker, S., Folprecht, G., Wöll, E., Decker, T., Endlicher, E., Röthling, N., Schuster, T., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605521 · Cited by 176
Self-citationMonoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 176
International Journal of Clinical Oncology
(2013) · International Journal of Clinical Oncology · doi:10.1007/10147.1437-7772 · Cited by 175
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.